Ian Parker, DO
Clinical Cardiac Electrophysiology · Oklahoma City, OKNPI 1306262712
Payments from drug & device makers
Across 792 payments — averaging $442.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cordis US CORP.$276K
- Abbott$29K
- Medtronic$28K
- Boston Scientific$8K
- Atricure, Inc.$4K
- Pfizer$716
- plus $3K from 25 others
What the payments were for
- Consulting fees$1,0001%
- Grants$2,2943%
- Travel & lodging$36,41849%
- Food & beverage$33,03245%
- Education$1,0021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cordis US CORP. | 8 | $276,458 |
| Abbott | 238 | $28,880 |
| Medtronic(2 entities) | 298 | $27,992 |
| Boston Scientific | 96 | $8,209 |
| Atricure, Inc. | 22 | $4,469 |
| Pfizer | 33 | $716 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $587 |
| Impulse Dynamics (USA) Inc. | 5 | $356 |
| Philips North America LLC | 4 | $327 |
| Amgen | 9 | $268 |
| Irhythm Technologies, Inc. | 8 | $250 |
| Edwards Lifesciences | 5 | $239 |
| Biosense Webster, Inc. | 7 | $215 |
| Alnylam Pharmaceuticals Inc. | 5 | $197 |
| Stereotaxis Inc | 2 | $154 |
| Abiomed | 1 | $145 |
| Novartis | 5 | $122 |
| Janssen Scientific Affairs, LLC | 1 | $121 |
| Kestra Medical Technology Services, Inc. | 5 | $104 |
| Baxter Healthcare | 2 | $68 |
| AstraZeneca | 3 | $60 |
| Boehringer Ingelheim | 3 | $59 |
| Cardiva Medical, Inc. | 1 | $31 |
| Merck | 2 | $30 |
| Innovation Technologies Inc | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $25 |
| Viiv Healthcare Company | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Lantheus Medical Imaging, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSITE PRECISION$8,990
- ENSITE$7,054
- GENERAL - THERAPIES$5,171
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$3,970
- Ensite Cardiac Mapping System$2,528
- EnSite Precision Cardiac Mapping System$2,373
- Arctic Front$1,074
- EVERA MRI XT DR SURESCAN$986
- AURORA EV-ICD MRI SURESCAN$837
- Micra$782
- NA$780
- ARCTIC FRONT ADVANCE$700
- OPTIMIZER$592
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$498
- LINQ II$433
- CardioMEMS HF System$422
- ATRICLIP LAA EXCLUSION SYSTEM$359
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$293
- SelectSecure$288
- Rhythmia Mapping System$285
How this compares
$350,203 in reported general payments places this provider in the 90th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.
See all clinical cardiac electrophysiology providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 171 | $204,287 |
| MultaqDronedarone Hcl | 43 | $62,270 |
| EntrestoSacubitril/Valsartan | 42 | $40,878 |
| FarxigaDapagliflozin Propanediol | 19 | $20,487 |
| JardianceEmpagliflozin | 20 | $18,393 |
| XareltoRivaroxaban | 14 | $18,124 |
| Dofetilide | 38 | $5,737 |
| Amiodarone Hcl | 168 | $4,881 |
| Flecainide Acetate | 117 | $3,720 |
| SotalolSotalol Hcl | 57 | $2,086 |
| Metoprolol Succinate | 116 | $1,595 |
| Carvedilol | 139 | $1,371 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 12 | $1,269 |
| ClopidogrelClopidogrel Bisulfate | 58 | $822 |
| PaceroneAmiodarone Hcl | 11 | $572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $716 | $204,287171 claims |
| Sanofi-aventis U.S. LLCMultaq | $25 | $62,27043 claims |
| NovartisEntresto | $122 | $40,87842 claims |
| AstraZenecaFarxiga | $60 | $20,48719 claims |
| Boehringer IngelheimJardiance | $59 | $18,39320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.
Other clinical cardiac electrophysiology in Oklahoma City
- Warren JackmanOklahoma City$2.3M
- John SummersOklahoma City$1M
- Coty JewellOklahoma City$335K
- Sunny PoOklahoma City$272K
- Charles TeOklahoma City$127K
- Paul GarabelliOklahoma City$119K
- Sean HalleranOklahoma City$107K
- Richard LaneOklahoma City$38K
- Jack CollierOklahoma City$36K
- Terrance KhastgirOklahoma City$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.